Asset Details
Do you wish to reserve the book?
Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV
Do you wish to request the book?
Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV
2019
Overview
Recombinant vesicular stomatitis virus–Zaire Ebola virus (rVSV-ZEBOV) is the most advanced Ebola virus vaccine candidate and is currently being used to combat the outbreak of Ebola virus disease (EVD) in the Democratic Republic of the Congo (DRC). Here we examine the humoral immune response in a subset of human volunteers enrolled in a phase 1 rVSV-ZEBOV vaccination trial by performing comprehensive single B cell and electron microscopy structure analyses. Four studied vaccinees show polyclonal, yet reproducible and convergent B cell responses with shared sequence characteristics. EBOV-targeting antibodies cross-react with other
Ebolavirus
species, and detailed epitope mapping revealed overlapping target epitopes with antibodies isolated from EVD survivors. Moreover, in all vaccinees, we detected highly potent EBOV-neutralizing antibodies with activities comparable or superior to the monoclonal antibodies currently used in clinical trials. These include antibodies combining the IGHV3–15/IGLV1–40 immunoglobulin gene segments that were identified in all investigated individuals. Our findings will help to evaluate and direct current and future vaccination strategies and offer opportunities for novel EVD therapies.
Analysis of monoclonal antibody responses to the Ebola virus vaccine rVSV-ZEBOV in human volunteers.
Publisher
Nature Publishing Group US,Nature Publishing Group
Subject
/ Adult
/ Antibodies, Neutralizing - immunology
/ Antibodies, Viral - immunology
/ Antibody Formation - immunology
/ Biomedical and Life Sciences
/ Ebola Vaccines - administration & dosage
/ Ebola Vaccines - adverse effects
/ Female
/ Hemorrhagic Fever, Ebola - immunology
/ Hemorrhagic Fever, Ebola - prevention & control
/ Hemorrhagic Fever, Ebola - virology
/ Humans
/ Immunity, Humoral - immunology
/ Male
/ Mapping
/ Vaccination - adverse effects
/ Vaccines
